Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MLTX by emailGet an email when MLTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MLTX, unsubscribe in one click. Privacy
📣 What MLTX Says Is Next
by 2035 · “Real-world data in the United States indicate that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15 billion by 2035.”
Company press release, Aug 10, 2026 · SEC filing
at the end of 2026 · “PsA/axial spondyloarthritis (axSpA): Expected to report results from the P-OLARIS trial at the end of 2026 or early 2027 -Ends- 2 MoonLake Immunotherapeutics MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody ® for the treatment of inflammatory disease, to revolutionize outcomes for patients.”
Company press release, Aug 10, 2026 · SEC filing
H2 2026 · “Palmoplantar Pustulosis (PPP): Expected to commence enrollment in H2 2026”
Company press release, Aug 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MLTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MLTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.